Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 11/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | FABP2 | P12104 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859853 | 0.78 | PTGS2 (0.48) | AKR1C3AKR1C2PTGS2CYP2C19APP | |
| SCHEMBL11663434 | 0.75 | LMNA (0.37) | LMNASTING1MAPK1HTTRAB9A | |
| SCHEMBL11663436 | 0.73 | TNFSF11 (0.43) | LMNAMAPK1HTTRAB9ATDP2 | |
| SCHEMBL6932963 | 0.71 | GAA (0.40) | LMNAMAPK1HTTRAB9ATDP2 | |
| SCHEMBL9730519 | 0.70 | MAPT (0.47) | LMNAMEN1KMT2AMAPTHPGD | |
| SCHEMBL8141510 | 0.70 | FGFR1 (0.34) | LMNAMAPK1HTTRAB9ATDP2 | |
| SCHEMBL11847964 | 0.69 | CXCR5 (0.35) | — | |
| SCHEMBL10086404 | 0.67 | NPC1 (0.60) | AKR1C3AKR1C2PTGS2CYP2C19APP | |
| SCHEMBL8157270 | 0.67 | MAPT (0.43) | HTTMEN1KMT2AHTR2CMAPT | |
| SCHEMBL8157275 | 0.67 | MAPT (0.43) | HTTMEN1KMT2AHTR2CMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0910380-B1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | CELL PATHWAYS INC (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | OSI PHARMACEUTICALS, INC. | 2002-08-08 | — | — | US | disclosed |
| US-6403831-B1 | 5,6-DIFLUORO-2-METHYL-1-(3,4,5-TRIMETHOXY-BENZYLIDENE)-3-(N-BE NZYL)-INDENYL ACETAMIDE; ANTITUMOR AND ANTICARCINOGENIC AGENT USED TO TREAT PRECANCEROUS LESIONS | CELL PATHWAYS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-6232312-B1 | ADMINISTERING A COMBINATION OF INDENE AND PYRIMIDO(5,4-D)PYRIMIDINE DERIVATIVES TO TREAT PREPANCREATIC CANCER | CELL PATHWAYS, INC. | 2001-05-15 | — | — | US | disclosed |
| EP-0910380-A4 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | CELL PATHWAYS INC (US) | 2000-09-27 | — | — | EP | disclosed |
| US-6121321-A | IN CARRIER | CELL PATHWAYS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-6063818-A | Substituted benzylidene indenyl formamides, acetamides and propionamides | CELL PATHWAYS INC. (US) | 2000-05-16 | — | — | US | disclosed |
| US-5998477-A | MIXTURE OF DRUG AND CARRIER | CELL PATHWAYS INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0910380-A1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | Cell Pathways, Inc. (US) | 1999-04-28 | — | — | EP | disclosed |
| US-5776962-A | Lactone compounds for treating patient with precancerous lesions | CELL PATHWAYS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1997047303-A1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | CELL PATHWAYS, INC. (US) | 1997-12-18 | — | — | WO | disclosed |
| US-5696159-A | Lactone compounds for treating patients with precancerous lesions | CELL PATHWAYS, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| US-5643959-A | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | CELL PATHWAYS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0723442-A4 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS INC (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0723442-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996003987-A1 | LACTONE COMPOUNDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | VHL, IDH3A, GLI2 | AKR1C3 170/4885AKR1C2 143/4885PTGS2 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.